| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46375 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Oct, 2026
(3 years from now) | |
| USRE46365 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Jan, 2028
(4 years from now) | |
| US9108975 | BDSI | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same |
Nov, 2031
(8 years from now) | |
| US10952968 | BDSI | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
May, 2033
(9 years from now) | |
Symproic is owned by Bdsi.
Symproic contains Naldemedine Tosylate.
Symproic has a total of 4 drug patents out of which 0 drug patents have expired.
Symproic was authorised for market use on 23 March, 2017.
Symproic is available in tablet;oral dosage forms.
Symproic can be used as treatment of opioid-induced constipation.
Drug patent challenges can be filed against Symproic from 2021-03-23.
The generics of Symproic are possible to be released after 13 May, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 23, 2022 |
Drugs and Companies using NALDEMEDINE TOSYLATE ingredient
NCE-1 date: 2021-03-23
Market Authorisation Date: 23 March, 2017
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET;ORAL
SYMPROIC family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic